AUS
NZ
UK
CA
USA
IND
Highlights
- NANOBIOTIX begins Phase 2 CONVERGE study for JNJ-1900 (NBTXR3) in Stage 3 non-small cell lung cancer.
- The study evaluates the first-in-class radioenhancer JNJ-1900 as part of chemoradiation treatment.
- Partnership with Janssen Pharmaceutica advances the clinical development of NBTXR3 for cancer therapies.
NANOBIOTIX (NASDAQ:NBTX), a leading biotechnology company specializing in nanoparticle-based therapeutic approaches, has announced a significant milestone in the development of its radioenhancer, JNJ-1900 (NBTXR3). The first patient has been dosed in the Phase 2 CONVERGE study, a randomized controlled clinical trial assessing JNJ-1900 as a treatment for patients with Stage 3 unresectable non-small cell lung cancer (NSCLC). This study evaluates the use of JNJ-1900 in combination with standard chemoradiation followed by consolidation durvalumab, an immunotherapy agent.
The CONVERGE study (NCT06667908) is being sponsored by Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson, under a global license agreement. This trial represents an important step forward in the clinical development of JNJ-1900, positioning it as a potential first-in-class treatment for lung cancer. The study will provide critical data to evaluate the safety and efficacy of JNJ-1900 in improving patient outcomes.
Laurent Levy, Chief Executive Officer and Chairman of the Executive Board of Nanobiotix, expressed optimism about the trial's potential, stating, “We believe the true value of JNJ-1900 (NBTXR3) is driven by its potential to address the unmet needs of the millions of patients each year who receive radiotherapy as part of their treatment.” Levy further noted, “With a clear path to potential registration in head and neck cancer established through NANORAY-312, the first patient dosed in the CONVERGE study in non-small cell lung cancer brings us another step closer to delivering for the large number of patients JNJ-1900 (NBTXR3) is designed to serve.”
The CONVERGE study builds upon the promising results seen in earlier trials and aims to expand the therapeutic use of JNJ-1900 beyond head and neck cancers, where it has already shown significant potential. By enhancing the effects of radiation therapy, JNJ-1900 aims to improve tumor control and increase survival rates for patients with difficult-to-treat cancers like NSCLC. This trial is expected to generate valuable data that will help shape the future of radioenhancer therapies in oncology.
Nanobiotix's partnership with Janssen Pharmaceutica is a key element in the advancement of this cutting-edge treatment. The collaboration leverages Janssen's expertise in oncology and Nanobiotix’s innovative nanoparticle-based technology, creating a powerful combination to target cancers more effectively.
As part of its broader mission, Nanobiotix continues to focus on addressing the unmet needs of cancer patients by developing novel therapies that expand treatment options. The company’s lead product, JNJ-1900 (NBTXR3), is designed to enhance the effectiveness of radiotherapy, potentially transforming how cancer is treated.
